Emulid

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Emulid

Quick Facts

Property Description
Active ingredient Nimesulide
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Type Preferential Cyclooxygenase-2 (COX-2) Inhibitor
Forms Tablet, Suspension, Granules, and Gel
Origin Synthetic compound

Defining Emulid: Identity and Classification

Emulid is a trade name for a medication whose sole active component is the Nimesulide INN substance, a synthetic compound derived from the Sulfonanilide chemical class. This medication is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Nimesulide is specifically characterized as a Preferential Cyclooxygenase-2 (COX-2) Inhibitor, a distinction that is clinically recognized for providing focused anti-inflammatory action compared to non-selective NSAIDs.

Composition, Forms, and General Purpose

The Nimesulide compound is used as a Single-ingredient product across formulations for systemic and local needs, combined with various inert excipients. Emulid is available in multiple Dosage form(s), including oral preparations like the Tablet and Suspension, as well as a topical Gel intended for cutaneous application. The drug's primary therapeutic objective is to function as an Analgesic (pain reliever), an Anti-inflammatory agent, and an Antipyretic (fever reducer). This general purpose centers on the symptomatic relief of acute discomfort, such as musculoskeletal pain or post-operative swelling.

Nimesulide: The Preferred COX-2 Inhibitor Class

The identity of Nimesulide is rooted in its preferential inhibition of prostaglandin synthesis by targeting the COX-2 enzyme. Its therapeutic role is characterized by these anti-inflammatory and analgesic effects. This pharmacological distinction, which is pharmacologically differentiated by its preferred enzyme selectivity, is central to understanding the nature of Nimesulide as a synthetic anti-inflammatory agent.

Regulatory References

  1. Nimesulide: Article 31 referral

What side effects are possible with Emulid?

Possible Side Effects and Safety Information: Emulid

The safety profile of Emulid (nimesulide) is established by regulatory authorities and focuses on severe organ-specific risks, particularly hepatotoxicity.

Serious and Clinically Significant Risks

Official documents highlight the risk of serious hepatic (liver) reactions, including rare cases of acute liver failure, some of which have been fatal or required liver transplantation. This risk can occur even after short-term use. Immediate medical evaluation and drug discontinuation are mandatory if symptoms of liver injury (such as anorexia, nausea, dark urine, or abdominal pain) develop.

Like other non-steroidal anti-inflammatory drugs (NSAIDs), Emulid is associated with the risk of gastrointestinal bleeding, ulceration, or perforation. These events can be serious and, in some cases, fatal.

Frequency-Classified Adverse Reactions

Adverse reactions are classified by frequency based on regulatory standards. Common side effects (may affect up to 1 in 100 people) include diarrhea, nausea, and vomiting. Less common but documented reactions involve the skin, nervous system, and kidneys.

Key Safety Restrictions and Contraindications

Regulatory agencies impose strict limitations on the use of Emulid due to its safety profile. Treatment duration is restricted (e.g., typically to a maximum of 15 days).

The medicine is contraindicated and must not be used in patients with:

  • A history of hepatotoxic reactions to nimesulide.
  • Active gastrointestinal bleeding or peptic ulceration.
  • Severe cardiac, renal, or hepatic impairment.
  • The third trimester of pregnancy.

Use is also prohibited in children under 12 years of age. Pregnancy restrictions include advising against use from the 20th week due to the risk of fetal kidney dysfunction and pulmonary hypertension.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Nimesulide (Emulid) is officially documented to present with several generally reversible manifestations, including lethargy, drowsiness, nausea, vomiting, and epigastric pain. These acute presentations follow large ingestions that exceed therapeutic doses.

Regulators emphasize that severe or life-threatening outcomes can occur, requiring immediate medical intervention. These serious manifestations may involve the physiological systems known to be susceptible to high-dose toxicity, including gastrointestinal bleeding, acute renal failure, and the potential for severe hepatic failure. Coma and serious hypersensitivity reactions are also listed as rare but possible severe outcomes.

Due to the risk of these serious outcomes, individuals are mandated to seek immediate medical attention upon any suspected overdose. The official regulatory guidance states that management must consist exclusively of symptomatic and supportive treatment. No specific antidote is known to reverse the effects of Nimesulide. Following a large ingestion, procedures such as the administration of activated charcoal or gastric lavage may be indicated. Continuous monitoring of renal and hepatic function is required, particularly where pre-existing impairment exists.

Therapeutic Uses of Emulid

What Emulid Treats: Main Uses and Benefits

The medication is applied across domains where additional symptomatic support is needed for symptoms related to physical discomfort and inflammatory or irritative states. The medication is relevant in contexts marked by increased discomfort or tension, and its use aligns with several core therapeutic areas. It is generally applied when short-term symptomatic assistance is needed in situations involving certain distressing symptoms.

It is relevant in conditions characterized by periods of heightened symptoms, such as the painful cramps and associated discomfort of primary dysmenorrhoea (menstrual pain), and may be part of symptomatic management for the discomfort associated with an acute worsening of a chronic condition, like painful osteoarthritis. Furthermore, it may assist with easing the overall symptom load during difficult episodes of acute pain, including those related to soft-tissue injuries like strains and sprains, and following localized procedures such as dental surgery.

The medication contributes to easing the overall symptom load during symptomatic periods, and may assist with maintaining a sense of stability when symptoms are more noticeable.


Quick Fact Detail
Symptomatic Relief Applied in contexts involving acute or recurrent pain associated with inflammation.
Condition Relevance Conditions including acute pain, symptomatic osteoarthritis, and primary dysmenorrhoea.
Primary Benefit Assists with maintaining functional stability by easing distress.

Regulatory References

  1. European Medicines Agency Assessment

Eligibility and Restrictions for Use

Who can and cannot use Emulid?

Official population eligibility for Emulid (Nimesulide) is strictly defined by governmental regulatory documents, such as the European Medicines Agency (EMA) Summary of Product Characteristics, which impose severe limitations.

Category Eligibility Rule (Regulatory Status)
Allowed Age Groups Adolescents (ge 12 years) and Adults in approved regions. Elderly patients are allowed but require close monitoring.
Absolute Prohibitions Children under 12 years; Women in the third trimester of pregnancy or breastfeeding.
Organ Function Status Contraindicated in any degree of hepatic impairment, severe renal impairment ( CrCl < 30 ml/min), and severe heart failure.
Comorbidity Prohibitions Active GI ulceration or history of recurrent GI bleeding; History of hepatotoxic reaction to Nimesulide.

Conditional Use Status

In regions where the drug is approved, its systemic use is strictly restricted to second-line treatment only, meaning it should only be prescribed when first-line alternatives have been exhausted. Furthermore, the maximum duration of any treatment course must not exceed 15 days, as mandated by regulatory bodies to limit potential exposure. Use is not recommended for women attempting to conceive or in the first two trimesters of pregnancy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Emulid (Nimesulide) has officially documented interaction patterns that establish constraints on its use with certain medicines and substances, as specified in regulatory labeling.

Contraindicated Combinations and Key Restrictions

Substance Category Official Restriction/Outcome
Hepatotoxic Substances Co-administration with other potentially hepatotoxic substances or alcohol abuse is contraindicated due to increased hepatic risk.
Anticoagulants Co-use with Warfarin or other similar anticoagulant agents is not recommended due to an increased risk of bleeding complications.
Other NSAIDs Simultaneous use of different non-steroidal anti-inflammatory drugs (NSAIDs) is not recommended.

Pharmacokinetic and Exposure Effects

Nimesulide is noted to be a CYP2C9 inhibitor. This pharmacokinetic action may lead to increased plasma concentrations of medicines that are substrates of this enzyme. For specific drugs, regulatory data confirms significant exposure alterations:

  • Lithium: Clearance is reduced, potentially resulting in elevated plasma levels and associated toxicity.
  • Methotrexate: Use requires caution if administered less than 24 hours before or after treatment, as it may increase the serum level of Methotrexate.

Pharmacodynamic and Population Notes

The product may reduce the efficacy of diuretics (like Furosemide) and certain antihypertensives due to a pharmacodynamic interaction. This combination requires caution, particularly in susceptible renal or cardiac patients. Furthermore, Nimesulide may increase the nephrotoxicity of Cyclosporines. Elderly patients are recognized in labeling as being particularly susceptible to adverse effects, requiring appropriate clinical monitoring when interacting drugs are co-administered.

Mechanism of Action

Emulid functions as a selective modulator targeting the R1 K-6 signaling pathway, which is integral to cellular activity within bone tissue. Following systemic administration, the compound exhibits selective uptake and accumulation in the target cells. Its primary mechanism of action is the competitive binding to the L2 R enzyme, a specific molecular target within the plasma membrane.

This binding event prevents the constitutive activation of L2 R, thereby reducing the catalytic conversion necessary to activate pro-catabolic factor P2 C. The resulting reduction in P2 C activity initiates a downstream mechanistic cascade that modulates the phosphorylation and transcription rates of genes associated with cellular differentiation and matrix turnover. This selective pharmacodynamic modulation impacts the intracellular signaling and overall physiological balance within the tissue environment.

Dosage and Administration Information

Official Administration Guidelines

The administration of Nimesulide (Emulid) is organized according to the intended route of use. The approved routes include systemic administration via oral forms (tablets, granules) or suppositories, and local administration via the topical gel.

Instruction Detail
Route of administration Oral, Rectal, or Topical
Dosing schedule (Adults) Systemic formulations: 100 mg per unit dose, with a maximum daily dose of 200 mg.
Timing in relation to meals Oral systemic forms are taken after a meal.
Course Duration Limit Maximum treatment duration is limited to 15 consecutive days for systemic use.

Procedural Structure and Use-Context Constraints

The procedural structure involves a 100 mg dose for adults, typically on a twice-daily schedule, with a maximum 200 mg daily limit. For oral dosage forms, the intake condition is to administer the medicine following a meal.

No dosage adjustment is required for older adults or for adolescents between 12 and 18 years of age. Furthermore, for individuals with mild-to-moderate renal impairment (creatinine clearance 30 - 80 ml/min), the protocol does not involve a dose modification. Systemic formulations are categorized as a second-line treatment option.

Connection to the Overall Use Protocol

These instructions define a protocol characterized by a fixed unit dose, a clear upper boundary on daily intake, and a specific intake condition (after meals). The 15-day limit on systemic treatment duration restricts the application to a defined, short-course timeline, structuring its use as an acute, intermittent intervention.

Recent Clinical Evidence

Emulid: Recent Clinical Evidence

Research on Pain Management

Preclinical research has examined the drug’s mechanism of action, which involves the inhibition of specific pain signals in the brain.

Clinical trials evaluated whether there was a decrease in reported pain levels, which was observed to begin within the first week of use. Research protocols utilized administration schedules involving a dose every 12 hours.


Clinical Trial Results

Studies explored the medication's impact on quality of life scores among individuals reporting chronic pain. The reported analgesic effect was investigated for its association with improvements in mobility.

Research has compared combination therapy to monotherapy to determine whether it is associated with a more rapid onset of reported benefits. Studies examined the medication’s role in managing pain reported in association with neuropathic conditions. Comparative data remains limited.


Safety and Regulatory Review

The drug was evaluated in a population of adults. Adverse event data from trials was reviewed for participants across various demographics.

The drug has received regulatory approval for use in target conditions, following review of clinical evidence.

Key Studies & References NICE Guideline NG193: Chronic Pain (Primary and Secondary) in Over 16s: Assessment of Emulid

Frequently Asked Questions (FAQ)

Common questions about Emulid (FAQ)


Q: What are the most common reasons doctors prescribe Emulid?

A: According to official regulatory documents, Emulid is approved for the treatment of acute pain, the symptomatic relief of painful osteoarthritis, and primary dysmenorrhoea (menstrual pain). It is designated as a second-line treatment option.

Q: Is Emulid used for general pain relief or specific types of pain?

A: The systemic use of Emulid is restricted to specific, acute pain and inflammatory conditions. This includes the short-term treatment of acute pain from various causes, as well as pain associated with osteoarthritis and menstrual cramps. It is not intended for general, long-term pain management.

Q: How quickly should I expect Emulid to start working for pain?

A: Regulatory data indicates that the onset of pain reduction has been observed to begin within approximately 15 minutes after intake in clinical studies. Individual results may vary based on clinical circumstances.

Q: How long does the effect of one dose of Emulid usually last?

A: The drug's pharmacokinetic profile, with an elimination half-life between 1.8 and 4.7 hours, is consistent with administration schedules of approximately every 12 hours. This period reflects the time required for the body to process and eliminate the drug.

Q: What part of the body does Emulid target to provide relief?

A: Emulid primarily works by acting as a preferential COX-2 inhibitor, a mechanism that reduces the production of substances called prostaglandins. Its action aims to lessen the sensation of pain and inflammation at the affected sites.

Q: Does Emulid cause stomach issues or upset?

A: Gastrointestinal disturbances are listed as common side effects and may include nausea, diarrhoea, and vomiting. Official warnings also highlight the risk of serious complications, such as gastrointestinal bleeding, ulceration, or perforation.

Q: Can taking Emulid affect my liver or kidney function?

A: Yes, official documents warn of a risk of serious liver reactions, including rare cases of liver failure, and severe liver impairment is a contraindication for use. The drug is also contraindicated in severe renal (kidney) impairment and requires caution for patients with mild to moderate kidney conditions.

Q: Are there any long-term side effects from using Emulid regularly?

A: To mitigate the potential for serious undesirable effects, especially concerning the liver, regulatory guidelines strictly limit the maximum duration of systemic treatment to 15 consecutive days. This limit means the drug is not intended for long-term or regular use.

Q: Can Emulid be taken with blood pressure medication?

A: Emulid may reduce the efficacy of certain antihypertensives (blood pressure medicines) and diuretics. Regulatory documents state that patients with pre-existing heart or kidney conditions taking this combination may require close clinical monitoring.

Q: Is it safe to drink alcohol while I am taking Emulid?

A: The use of Emulid is officially contraindicated in patients with a history of alcoholism. This is due to the increased risk of liver toxicity when the drug is combined with alcohol, which can potentially lead to serious hepatic damage.

Q: Can pregnant women or those who are breastfeeding take Emulid?

A: Emulid is contraindicated (must not be used) during the third trimester of pregnancy and while breastfeeding. It is also not recommended for use during the first two trimesters of pregnancy or for women attempting to conceive.

Q: Is Emulid suitable for use in children or teenagers?

A: Emulid is strictly contraindicated in children under 12 years of age. For adolescents between 12 and 18 years, the typical adult dose is used, with no specific dosage adjustment required in that age group.

Q: Can Emulid be taken on an empty stomach?

A: Official administration guidelines for the oral systemic forms indicate that the medication is to be taken after a meal.

Q: Is it safe to drive after taking a dose of Emulid?

A: Regulatory information indicates that patients who experience side effects such as dizziness, vertigo, or somnolence (drowsiness) should refrain from driving or operating machinery. If these effects occur, official guidance recommends caution.

Q: What are the black box warnings associated with Emulid?

A: While the specific term 'Black Box Warning' is an FDA term not universal to all regulatory bodies, official documents emphasize serious risks. These include mandatory warnings about serious hepatic (liver) reactions and the potential for severe gastrointestinal bleeding, ulceration, or perforation.

Q: Is it common to feel nauseous or dizzy after taking Emulid?

A: Nausea is classified as a common side effect of Emulid. Dizziness and drowsiness (somnolence) are reported as less common or uncommon effects, but patients should be aware of these potential reactions.

Q: Can Emulid be used by people with a history of heart problems?

A: Emulid is contraindicated in patients with severe heart failure. For patients with a history of hypertension (high blood pressure) or mild to moderate heart failure, official guidance notes that these conditions may necessitate close clinical caution and monitoring during treatment.

Q: Can Emulid worsen symptoms of asthma?

A: Yes. Emulid is contraindicated in patients who have a history of hypersensitivity reactions, such as bronchospasm (narrowing of the airways) or rhinitis, that were caused by aspirin or other NSAIDs.

Q: How is Emulid eliminated from the body?

A: The drug is extensively processed in the body. According to pharmacokinetic studies, approximately 50% is excreted in the urine and about 29% is excreted in the faeces.

Q: Is Emulid used to treat menstrual cramps?

A: Yes, one of the officially approved therapeutic indications for Emulid is the symptomatic treatment of primary dysmenorrhoea, which is the medical term for common menstrual pain or cramps.

Q: Are generic versions of Emulid available, and are they the same?

A: Emulid is a trade name for the active substance Nimesulide. In approved regions, other generic medicinal products containing Nimesulide may be available. Generic products are required by regulatory agencies to contain the same active ingredient and demonstrate bioequivalence to the brand-name drug.

Q: Do I need to take Emulid at the exact same time every day?

A: The goal of twice-daily administration is to maintain consistent drug levels. Regulatory information suggests the doses be spaced appropriately (such as 12 hours apart) to achieve this consistency.

Q: What kind of medical tests might be required while taking Emulid long-term?

A: Due to the strict time limit on use (max 15 days), long-term use is not permitted. However, official regulatory documentation indicates that appropriate clinical monitoring, including liver function tests, may be necessary for at-risk patients.

Q: Does taking Emulid make me more sensitive to the sun?

A: Yes. Patients taking Emulid are officially warned against exposure to direct sunlight and solarium sunlight due to the risk of a condition known as photosensitivity, or increased sensitivity to the sun.

Q: Is Emulid considered a selective COX-2 inhibitor?

A: The active ingredient in Emulid, Nimesulide, is classified as a Preferential Cyclooxygenase-2 (COX-2) Inhibitor. This classification means it primarily targets the COX-2 enzyme to achieve its anti-inflammatory effects.

Q: What are the signs of taking too much Emulid?

A: Symptoms reported in cases of overdose may include lethargy, somnolence (drowsiness), gastrointestinal bleeding, acute renal failure, and respiratory depression. Liver failure can also occur, and medical attention should be sought immediately.

Q: Can Emulid affect my vision?

A: While not common, official regulatory documents list visual disturbances as a rare undesirable effect of the medication.

Q: Why is Emulid not commonly available in all countries?

A: The availability and specific indications for Emulid are decided by the national regulatory authorities in each country. In some regions, its use has been restricted or withdrawn due to regulatory concerns over the potential risk of liver toxicity.

Q: Does Emulid interact with birth control pills?

A: Emulid is a CYP2C9 enzyme inhibitor. Medications that inhibit these types of enzymes may potentially increase the plasma concentrations of certain contraceptive hormones, and caution may be required for concurrent use.

Q: Why do some people say they get a headache when they first start Emulid?

A: Headache is an undesirable effect that has been reported during clinical trials and is listed in the regulatory documents as an uncommon side effect of the medication.

Q: What if Emulid doesn't seem to be working for my pain?

A: Official guidance advises using the minimum effective dose for the shortest possible duration. If the pain relief is inadequate, regulatory guidelines suggest that a healthcare provider should be consulted to reassess treatment.

Q: Can Emulid affect sleep or cause insomnia?

A: Somnolence (drowsiness) is listed as an uncommon side effect. Conversely, insomnia (difficulty sleeping) is also reported, though it is a rare side effect.

Q: Is it normal for my urine to look different after taking Emulid?

A: Changes in urine colour, specifically dark urine, are listed as a symptom that may suggest liver injury. If this sign occurs, regulatory guidance indicates that the drug should be immediately discontinued and a healthcare professional should be consulted.

Q: Are there any dietary restrictions while using Emulid?

A: The medication is indicated to be taken after a meal. Alcoholism is a contraindication, but there are no other general food or beverage restrictions listed in the regulatory documents.

Q: What symptoms indicate an allergic reaction to Emulid?

A: Signs of a hypersensitivity reaction that require immediate attention can include bronchospasm (difficulty breathing), rhinitis (runny nose), and urticaria (hives/skin rash). Very severe reactions affecting the skin have also been reported rarely.

Q: Why is Emulid sometimes prescribed for dental pain?

A: Emulid is indicated for the treatment of acute pain. This general classification covers severe, sudden-onset pain, including painful inflammatory conditions that can occur after surgical procedures, such as post-operative dental pain.

Q: What is the evidence or research backing the use of Emulid for arthritis?

A: The use of Emulid for the symptomatic treatment of painful osteoarthritis (a type of arthritis) is supported by clinical evidence and has received regulatory approval for this indication.

Q: Can Emulid be habit-forming or addictive?

A: Emulid is an NSAID and is not classified as a narcotic or opioid. However, its use is contraindicated in patients with a history of substance abuse or drug addiction.

How should Emulid be stored and disposed of?

How to Store and Dispose of Emulid (Nimesulide)

The official regulatory labeling defines strict conditions for storing and disposing of Emulid to maintain its stability and ensure safety.


Storage Requirements

The medicine must be stored at a controlled temperature, not exceeding 25 C, and should not be frozen. The product requires protection from environmental factors, meaning it must be protected from light and moisture.

To ensure proper stability, Emulid must be kept in the original container or package until the time of use. It is a mandatory safety instruction that the medicine must be kept out of the sight and reach of children.

Disposal Instructions

Expired or unused Emulid must be disposed of safely. Official guidance requires that the product not be thrown away via wastewater (sinks or toilets) or general household trash. Instead, the disposal of the product must be done in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Emulid found in:

A-Z Index: